A Children's Health allocator leaves to build a secondaries firm

Seaman, a former allocator at Children's Health, has launched Gordian Investment Group, a secondaries firm that Private Equity International, which first reported the launch on September 15, describes as focused on overlooked deals. The premise is that institutional investors often hold the appetite and the capital for secondaries transactions and still fail to complete them, and that a firm built to finish those deals can carve out a business between them.

The pitch locates the bottleneck in sourcing, diligence, and the ability to close on a timetable an institutional committee can meet, rather than in committed capital, and it is more specific than most new firms offer—cutting against an established trend. Secondaries capital has grown faster than the supply of clean, well-documented deals, a development this publication has tracked, with buyers paying for structure in place of price discovery. A manager selling throughput rather than a balance sheet is betting that the scarce input is execution labor—a bet that, if right, makes a lean specialist viable and leaves the largest platforms paying for scale they cannot convert into closings.

An LP's seat is a revealing place from which to build because it is where deals are lost more often than won, and where the mechanical reasons for the losses—consent timing, information gaps, a seller's reluctance to move—are visible in a way they are not from the outside. The developed end of the market, meaning NAV loans, collateralized fund obligations, and minority-stake sales, rewards structuring desks and absorbs the industry's attention; the mid-market LP-led trade is where a small team can compete on speed, which suggests the 'overlooked' label points at situations too small or too messy to interest the biggest buyers.

The messiness is the risk, because transactions that institutions fail to finish are rarely the clean ones; they stall on incomplete data, contested marks, or a seller who will not take the price a buyer needs to underwrite. A firm promising follow-through is accepting risk where disclosure is thinnest, and thin disclosure is where this market has been substituting structure for price discovery. Gordian's differentiation is likely to be an appetite for that risk as much as a process advantage, and the first few exits will separate the two.

Unstated in the launch coverage are the capitalization, whether it raises third-party money or invests as a principal, at what size, or which LPs it will serve. Those choices describe two different businesses. A firm working LP-led mid-market stakes competes with every holder of dry powder; a firm working GP-led situations, where continuation vehicles have become a standing exit route, is selling diligence into a process slow to demand it. The first deal will say more than the formation notice did: what Gordian buys, from whom, and at what mark.